Pharma BD Deal Intelligence
Bayer's $1B-plus PROTAC collaboration handed Arvinas equity funding and platform validation across cardiovascular, oncology, and gynecological targets, but Bayer walked away in August 2024, terminating the human-disease pact and stripping Arvinas of that partner and its collaboration revenue.
Bayer and Arvinas to collaborate on human PROTAC therapies for cardiovascular, oncological, and gynecological diseases, with >$110M upfront/committed and…
Bayer and Arvinas to develop novel PROTAC candidates for humans and plants in deal worth over $1 billion with JV Oerth Bio
A decrease in revenue from Bayer of $1.1 million related to the termination of the Bayer Collaboration Agreement in August 2024.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
In June 2019, Bayer and Arvinas formed a collaboration to apply Arvinas' PROTAC targeted protein degradation platform to human therapeutics across cardiovascular, oncology, and gynecological disease targets, alongside a separate agricultural PROTAC joint venture (later named Oerth Bio). Per the companies' announcement, Arvinas received an upfront payment plus a direct Bayer equity investment, with total upfront/committed funding across the human collaboration, the equity stake, and the agricultural JV exceeding $110M, and was eligible for more than $685M in development milestones plus royalties. Bayer terminated the human collaboration agreement in August 2024; Arvinas recognized the loss of the associated collaboration revenue and Bayer no longer appears among its named partners.
$60.0B Global CV Therapeutics (2024)
Cardiovascular disease (CVD) encompasses a spectrum of disorders of the heart and blood vessels, including coronary heart disease, cerebrovascular disease (stroke and TIA), heart failure, peripheral arterial disease, and valvular and rhythm disorders. It is the leading cause of death in the United States, responsible for roughly 1 in every 5 deaths, and globally accounts for approximately 17-19 million deaths per year per WHO. Major modifiable risk factors include hypertension (affecting ~122M U.S. adults), hyperlipidemia, diabetes, tobacco use, obesity, physical inactivity, and unhealthy diet; non-modifiable factors include age, sex, family history, and genetics. Atherosclerosis underlies most ischemic CVD, with plaque rupture driving acute myocardial infarction and ischemic stroke. Evaluation uses ASCVD risk estimation, lipid panels, blood pressure and glucose assessment, and targeted imaging (echocardiography, coronary CTA/angiography, carotid duplex). Evidence-based management combines lifestyle modification with pharmacotherapy (statins, antihypertensives, antiplatelets, SGLT2 inhibitors and GLP-1 RAs in selected patients, guideline-directed medical therapy for heart failure) and procedural interventions (PCI, CABG, device therapy). Secondary prevention reduces recurrent events substantially.
PROTACs (proteolysis-targeting chimeras) degrade target proteins via the ubiquitin-proteasome pathway rather than inhibiting them. This enables targeting of undruggable proteins. Arvinas also has oncology PROTACs (vepdegestrant, ARV-766). The CV application is early-stage with targets undisclosed.
Bayer paid $65M upfront + $50M equity for PROTAC platform access targeting cardiovascular diseases.
Bayer ended the human PROTAC collaboration (CV, oncology, gynecological) in August 2024; Arvinas recognized the loss of associated collaboration revenue.
Bayer terminated the PROTAC collaboration in August 2024; partnership wound down before any program reached the clinic.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Arvinas, Inc. (this deal) | 2019 | $1.0B | 59 |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
| Bayer AG / Asklepios BioPharmaceuticals | 2020 | $2.0B | 49 |
← Browse all deals · How we score deals
More: 2019 deals · Bayer AG deals · Cardiovascular deals